GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocean Biomedical Inc (NAS:OCEA) » Definitions » Forward Rate of Return (Yacktman) %

Ocean Biomedical (Ocean Biomedical) Forward Rate of Return (Yacktman) % : 0.00% (As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Ocean Biomedical Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Ocean Biomedical's forward rate of return for was 0.00%.

The historical rank and industry rank for Ocean Biomedical's Forward Rate of Return (Yacktman) % or its related term are showing as below:

OCEA's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 10.77
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Ocean Biomedical Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Ocean Biomedical's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocean Biomedical Forward Rate of Return (Yacktman) % Chart

Ocean Biomedical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Forward Rate of Return (Yacktman) %
- - - -

Ocean Biomedical Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ocean Biomedical's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, Ocean Biomedical's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocean Biomedical's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocean Biomedical's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Ocean Biomedical's Forward Rate of Return (Yacktman) % falls into.



Ocean Biomedical Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Ocean Biomedical's Forward Rate of Return of Sep. 2023 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/3.9+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocean Biomedical  (NAS:OCEA) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Ocean Biomedical Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Ocean Biomedical's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocean Biomedical (Ocean Biomedical) Business Description

Industry
Traded in Other Exchanges
Address
55 Claverick Street, Room 325, Providence, RI, USA, 02903
Ocean Biomedical Inc is a biopharmaceutical company. It is dedicated towards partnering with inventor-scientists and research institutes to bridge the gap between basic research and clinical development, to get new medicines to the patients who need it most.
Executives
Robert J Sweeney officer: Chief Accounting Officer 20298 CRAIGEN CIRCLE, SARATOGA CA 95070
M Michelle Berrey director 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
William F Owens director C/O KEY ENERGY SERVICES, INC., 1301 MCKINNEY STREET, SUITE 1800, HOUSTON TX 77010
Inderjote S Kathuria officer: Chief Strategy Officer 19W060 AVENUE LATOUR, OAK BROOK IL 60523
Gurinder S Kalra officer: Chief Financial Officer 2305 WASHINGTON STREET, APT 301, SAN FRANCISCO CA 94115
Chirinjeev Kathuria director C/O UPHEALTH HOLDINGS, INC., 14000 S. MILITARY TRAIL #203, DELRAY BEACH FL 33484
Jerome Ringo director 1731 EMBARCADERO ROAD SUITE 200, PALO ALTO CA 94303
Poseidon Bio, Llc 10 percent owner OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Daniel Behr officer: EVP, Innov./Acad. P'ships Head OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Jack A Elias director OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Jonathan Kurtis director OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Elizabeth Ng director, officer: Chief Executive Officer OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Martin D Angle director OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Aesther Healthcare Sponsor, Llc 10 percent owner 515 MADISON AVE., SUITE 8078, NEW YORK NY 10022
Michael L Peterson director 17 CANARY COURT, DANVILLE CA 94526

Ocean Biomedical (Ocean Biomedical) Headlines

From GuruFocus

Taglich Brothers Initiates Coverage of Ocean Biomedical, Inc.

By sperokesalga sperokesalga 05-31-2023